PeptideLabs Logo
PeptideLabs
Quality Documentation
Back to all 64 profiles
Approved medicineApproved for specific uses

Community protocol · Afamelanotide

Afamelanotide: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: Melanotan I · MT-1 · MT-I · MT-1 Melanotin Receptor Type 1 · α-MSH analogue · Scenesse

Sources checked: 27 August 2026

Important safety and liability notice

This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

Afamelanotide

Promotes eumelanin production; approval is limited to a rare photosensitivity disorder.

Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.

Amounts, timing and cycles

Approved medicine

Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.

Amount status

Only the prescribing information for the exact approved product applies; brands, concentrations and indications are not interchangeable.

Profile evidence level: established.

Timing

Intervals, time of day and missed-dose handling depend on the product and indication.

No individual recommendation.

Cycle/duration

Approved medicines are clinician-managed treatment, not freely designed community cycles.

No individual recommendation.

No matching detail page found in the reference source

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Reconstitution and U-100 conversion

No generic calculator

For approved finished products, only the relevant prescribing information, original concentration and intended delivery system apply. Prefilled pens, syringes or product-specific vials must not be converted with a generic U-100 table.

For approved finished products, only the relevant prescribing information, original concentration and intended delivery system apply. Prefilled pens, syringes or product-specific vials must not be converted with a generic U-100 table.

Mechanism and research questions

Melanocortin-1 receptor agonist

Afamelanotide is classified as “Melanocortin-1 receptor agonist”. Promotes eumelanin production; approval is limited to a rare photosensitivity disorder. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Melanocortin receptor activation

This studies how activating melanocortin receptors affects pigmentation or sexual arousal signals, like a switch controlling different body functions depending on the receptor subtype. Skin pigmentation or physiological arousal markers are measured in studies.

02

Pigmentation and light response

This studies how skin pigment cells respond to signals that darken skin, potentially reducing sensitivity to sunlight, similar to how a photograph darkens with more exposure. Researchers typically measure skin pigment levels and light sensitivity in study participants.

03

Reproductive hormone signalling

This examines effects on hormone axes influencing libido, cycle, or fertility, similar to a feedback loop connecting several glands. Hormone levels and subjective questionnaires are measured in studies.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Cosmetic procedure forums

Users compare tanning or skin changes after using melanocortin-related substances, often based on shared photos rather than medical examination. Such posts do not establish reviewed safety, especially for unapproved variants.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

General wellness forums

Broader wellbeing impressions such as mood, sleep, and general feeling after using various products are exchanged here, usually without structured tracking. Such general impressions are not a substitute for targeted clinical examination.

Adverse effects and risk boundaries

  • Melanocortin activity can cause nausea, flushing, blood-pressure changes, headache, unwanted pigmentation and sexual adverse effects; non-selective analogues add uncertainty.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • Atypical moles/skin-cancer risk, uncontrolled blood pressure, cardiovascular disease, priapism risk and pregnancy require medical assessment.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Depending on the approved use, skin examination, blood pressure, nausea, pigment changes and indication-specific endpoints may be assessed.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Established

Approval covers only the specific photosensitivity disorder.

Published evidence

The described biological role is well established, or extensive regulator-reviewed human data exist for clearly defined products and uses. This does not automatically transfer to other products or purposes.

Afamelanotide selectively targets the melanocortin-1 receptor and is approved for a rare disorder, unlike the non-selective, unapproved Melanotan II.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Approved for specific uses

Prescription active ingredient for defined indications in at least one jurisdiction; not offered here.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.